Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
ApexOnco Front Page
Recent articles
Arcellx and AstraZeneca take centre stage.
But the Day One deal is still 29% below where the shares stood at the start of this year.
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
The response rate jumps to 30% with higher doses of IMA402.
New detalimogene bladder cancer data send the minnow’s stock up 47%.
After more discontinuations, a new deal brings in fresh blood.
The CD70-targeting CTX131 heads for the scrapheap.
